08:00 , Feb 20, 2006 |  BC Week In Review  |  Company News

Nymox, Lab21 sales and marketing update

NYMX granted Lab21 U.K. distribution rights to AlzheimAlert , a test for Alzheimer's disease (AD). Nymox Pharmaceutical Corp. (NYMX), St. Laurent, Quebec   Lab21 Ltd. , Fareham, U.K.   Business: Diagnostic  ...
08:00 , Nov 14, 2005 |  BC Week In Review  |  Clinical News

AlzheimAlert urine test regulatory update

NYMX filed with FDA "further proposals" for its PMA for AlzheimAlert urine test kit to diagnose Alzheimer's disease (AD). An FDA panel voted against approval of the kit in July (see BioCentury, July 25). NYMX...
07:00 , Sep 12, 2005 |  BC Week In Review  |  Company News

Nymox, Brainpharma S.L. sales and marketing update

Brainpharma will distribute NYMX's AlzheimAlert Alzheimer's disease (AD) test in Spain. Nymox Pharmaceutical Corp. (NYMX), St. Laurent, Quebec   Brainpharma S.L. , Madrid, Spain   Business: Diagnostic  ...
07:00 , Jul 25, 2005 |  BC Week In Review  |  Clinical News

AlzheimAlert urine test regulatory update

An FDA panel voted 5-2 against approval of a kit version of AlzheimAlert to diagnose Alzheimer's disease (AD). NYMX said the panel felt more data was needed, including postmortem verification and clarification of how to...
07:00 , Jul 25, 2005 |  BioCentury  |  Finance

Ebb & Flow

The venture community last week provided multiple examples of its low tolerance for risk. The three companies that all closed significant rounds last week -...
00:50 , Jul 19, 2005 |  BC Extra  |  Company News

FDA panel wants more AlzheimAlert data

Nymox (NYMX) said that on Friday an FDA panel voted 5-2 against approval of a kit version of AlzheimAlert to diagnose Alzheimer's disease (AD). NYMX said the panel felt more data was needed, including post-mortem...
07:00 , May 30, 2005 |  BC Week In Review  |  Clinical News

AlzheimAlert urine test regulatory update

NYMX's PMA for a kit version of the AlzheimAlert urine test to diagnose Alzheimer's disease (AD) is expected to be reviewed in July by FDA's Medical Devices Advisory Committee. The PMA was accepted for filing...
07:00 , May 2, 2005 |  BC Week In Review  |  Clinical News

AlzheimAlert urine test regulatory update

FDA's Medical Devices Advisory Committee will meet to discuss a PMA for a kit version of AlzheimAlert urine test to diagnose Alzheimer's disease (AD). The PMA was accepted for filing by FDA in May 2003....
08:00 , Feb 21, 2005 |  BC Week In Review  |  Company News

Nymox, Alifax sales and marketing update

Alifax will distribute NYMX's AlzheimAlert test kit in Italy. In November 2004, NYMX received CE Mark approval for the non-invasive urine test to measure the level of neural thread protein to diagnose Alzheimer's disease (AD)....
08:00 , Dec 13, 2004 |  BC Week In Review  |  Clinical News

AlzheimAlert urine test regulatory update

NYMX submitted an amendment to the PMA for AlzheimAlert test, which measures neural thread protein (NTP) levels to diagnose Alzheimer's disease (AD). The new PMA amendment is submitted in response to the remaining requirements from...